Imcyse SA, a biotechnology company developing active specific therapies for the treatment of severe chronic diseases, has entered into a research collaboration with Pfizer to develop an Imotope, a specific modified peptide, targeting rheumatoid arthritis (RA).   Pfizer will provide undisclosed funding for research and has an exclusive option to negotiate a license agreement following the research activities. Also, Pfizer will perform preclinical evaluation of another of Imcyse’s Imotopes targe...